Harpoon: Harpoon Therapeutics, Inc. (NASDAQ:HARP) to Post FY2025 Earnings of ($2.09) Per Share, Leerink Partnrs Forecasts

Harpoon Therapeutics, Inc. ( NASDAQ:HARP - Free Report ) - Equities research analysts at Leerink Partnrs issued their FY2025 earnings per share (EPS) estimates for shares of Harpoon Therapeutics in a report released on Monday, January 8th. Leerink Partnrs analyst J. Chang expects that the company will post earnings of ($2.09) per share for the year. Leerink Partnrs currently has a "Market Perform" rating on the stock. The consensus estimate for Harpoon Therapeutics' current full-year earnings is ($1.87) per share. Several other research analysts also recently weighed in on the company. Oppenheimer assumed coverage on Harpoon Therapeutics in a report on Friday, January 5th. They issued an "outperform" rating and a $23.00 price target for the company. Canaccord Genuity Group decreased their price target on shares of Harpoon Therapeutics from $80.00 to $40.00 and set a "buy" rating for the company in a research report on Thursday, September 14th. Citigroup decreased their price target on shares of Harpoon Therapeutics from $33.00 to $13.00 and set a "buy" rating for the company in a research report on Tuesday, October 24th. HC Wainwright cut shares of Harpoon Therapeutics from a "buy" rating to a "neutral" rating and upped their price objective for the company from $12.00 to $23.00 in a research report on Monday. Finally, TD Cowen assumed coverage on shares of Harpoon Therapeutics in a research report on Monday, November 20th. They issued an "outperform" rating for the company. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $24.75. Harpoon Therapeutics Price Performance Shares of Harpoon Therapeutics stock opened at $22.45 on Wednesday. The business has a 50 day moving average price of $10.72 and a 200 day moving average price of $8.10. The company has a market capitalization of $380.12 million, a P/E ratio of -2.56 and a beta of 2.10. Harpoon Therapeutics has a 1 year low of $3.11 and a 1 year high of $22.66. Harpoon Therapeutics ( NASDAQ:HARP - Get Free Report ) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.09) by $2.63. Harpoon Therapeutics had a negative return on equity of 893.55% and a negative net margin of 81.68%. The firm had revenue of $4.45 million during the quarter, compared to the consensus estimate of $8.33 million. Institutional Investors Weigh In On Harpoon Therapeutics A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in Harpoon Therapeutics by 5.6% during the first quarter. BlackRock Inc. now owns 1,809,686 shares of the company's stock worth $8,994,000 after acquiring an additional 95,355 shares during the period. Dimensional Fund Advisors LP raised its stake in Harpoon Therapeutics by 50.3% during the first quarter. Dimensional Fund Advisors LP now owns 103,267 shares of the company's stock worth $513,000 after acquiring an additional 34,578 shares during the period. Sequoia Financial Advisors LLC acquired a new stake in Harpoon Therapeutics during the first quarter worth about $66,000. Vanguard Group Inc. raised its stake in Harpoon Therapeutics by 2.7% during the first quarter. Vanguard Group Inc. now owns 1,288,202 shares of the company's stock worth $6,402,000 after acquiring an additional 34,392 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Harpoon Therapeutics by 309.3% during the first quarter. Renaissance Technologies LLC now owns 211,200 shares of the company's stock worth $1,050,000 after acquiring an additional 159,600 shares during the period. Institutional investors and hedge funds own 74.01% of the company's stock. Harpoon Therapeutics Company Profile ( Get Free Report ) Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Further Reading Five stocks we like better than Harpoon Therapeutics How to Capture the Benefits of Dividend Increases PriceSmart is a smart play for 2024 with multiple tailwinds How to Start Investing in Penny Stocks These 3 industrial stocks just got upgraded ahead of earnings How to Know Which Cryptocurrency to Buy: A Guide for Investors Hubbell, Rockwell stocks set to benefit from electrification boom Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .